Company Intelligence
Personalis
MedTwenty Company Score 74Cancer Genomics · Fremont, United States · Founded 2011
Minimal-residual-disease and tumour-informed sequencing company, being acquired by Tempus in a $1.5bn transaction.
Key facts
Employees380
Revenue$92m (FY2025)
Valuation$1.5bn (acquisition)
Last roundAcquired, September 2026
Funding history
| Date | Round | Amount | Lead investor |
|---|
Timeline
- 26 Sep 2026Agrees $1.5bn acquisition by Tempus.
Benchmarks, competitor comparison and export
Professional membership unlocks side-by-side competitor comparison, historical financial series and CSV export for this company.
Upgrade